Synonym
LAS195319; LAS-195319; LAS 195319;
IUPAC/Chemical Name
N-[4-(4-{[(1S)-1-(5-Methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo-[2,1-f ][1,2,4]triazin-2-yl)ethyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1H-indol-6-yl]sulfamide
InChi Key
PGFZGJZTPSVQMY-KRWDZBQOSA-N
InChi Code
InChI=1S/C29H26N10O3S/c1-16-9-11-38-25(16)29(40)39(19-6-4-3-5-7-19)28(36-38)17(2)35-27-24-22(14-32-26(24)33-15-34-27)21-12-18(37-43(30,41)42)13-23-20(21)8-10-31-23/h3-15,17,31,37H,1-2H3,(H2,30,41,42)(H2,32,33,34,35)/t17-/m0/s1
SMILES Code
O=S(N)(NC1=CC2=C(C(C3=CNC4=NC=NC(N[C@H](C(N(C5=CC=CC=C5)C6=O)=NN7C6=C(C)C=C7)C)=C43)=C1)C=CN2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Oral PI3Kδ inhibitors such as Idelalisib and Duvelisib have shown efficacy as anticancer agents and Idelalisib has been approved for the treatment of three B-cell cancers.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
594.65
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Erra M, Taltavull J, Bernal FJ, Caturla JF, Carrascal M, Pagès L, Mir M,
Espinosa S, Gràcia J, Domínguez M, Sabaté M, Paris S, Maldonado M, Hernández B,
Bravo M, Calama E, Miralpeix M, Lehner MD, Calbet M. Discovery of a Novel Inhaled
PI3Kδ Inhibitor for the Treatment of Respiratory Diseases. J Med Chem. 2018 Oct
29. doi: 10.1021/acs.jmedchem.8b00873. [Epub ahead of print] PubMed PMID:
30351000.